medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Jan. 28, 2022
Recognizing
that
anti-SARS-CoV-2
antibody
levels
wane
over
time
following
the
2-dose
SARS-CoV-2
mRNA
series,
FDA
approved
a
booster
dose
for
people
greater
than
12
years
old.
Limited
data
exist
on
whether
of
vaccine
results
in
protection
primary
series.
We
examined
total
and
neutralizing
antibodies
to
spike
protein
SARS-CoV-2,
against
Washington-1
(WA-1)
variants
concern
(VOC)
including
Beta,
Delta
Omicron
longitudinal
cohort.
Healthcare
workers
(HWs)
were
included
analysis
if
serum
was
collected
1)
within
14-44
days
post-dose2
an
(Timepoint
1,
TP1),
or
2)
at
least
8
months
2,
TP2),
3)
3,
TP3).
HWs
with
prior
covid-positive
PCR
excluded.
found
there
is
little
no
capability
series
omicron
variant,
capacity
any
variant
strain
tested
has
been
lost
by
8-months
post
two-dose
vaccination
However,
eliminates
immune
escape
observed
Neutralizing
titers
significantly
higher
all
post-boost
compared
The
nature
our
cohort
facilitated
paired
samples
pre
boost,
showing
15-fold
increase
neutralization
these
samples.
An
provides
quantity
quality
regimen
critical
provide
variant.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: July 13, 2022
Our
understanding
of
the
immune
responses
that
follow
SARS-CoV-2
infection
and
vaccination
has
progressed
considerably
since
COVID-19
pandemic
was
first
declared
on
11
th
March
in
2020.
Recovery
from
is
associated
with
development
protective
responses,
although
over
time
these
become
less
effective
against
new
emerging
variants.
Consequently,
reinfection
variants
not
infrequent
contributed
to
ongoing
pandemic.
vaccines
have
had
a
tremendous
impact
reducing
particularly
number
deaths
infection.
However,
waning
vaccine
induced
immunity
plus
emergence
necessitated
use
boosters
maintain
benefits
deaths.
Boosting
also
beneficial
for
individuals
who
recovered
developed
natural
immunity,
enhancing
This
review
summarizes
our
vaccination,
risks
very
important
role
boosting
plays
both
vaccinated
previously
infected
individuals.
Microbiology Spectrum,
Journal Year:
2022,
Volume and Issue:
10(5)
Published: Oct. 3, 2022
SARS-CoV-2
antibody
levels
wane
following
two-doses
of
mRNA
vaccination.
An
booster
dose
provides
increased
protection
against
hospitalization
and
death.
We
demonstrated
that
a
significant
increase
in
the
neutralization
Beta,
Delta
Omicron
variants
addition
to
an
vaccine
strain.
The
total
spike
IgG
measurements,
obtained
by
using
commercial
kits
target
protein
from
strain,
may
not
reflect
serum
concern.
IMPORTANCE
This
study
found
little
no
neutralizing
capability
2-dose
series
omicron
variant,
capacity
any
variant
strain
tested
was
lost
8-months
post
series.
However,
eliminated
immune
escape
observed
Even
more,
titers
were
significantly
higher
for
all
post-boost,
compared
post-two-dose
Our
data
are
unique,
paired
samples
eliminate
potential
confounders
impact
response.
Notably,
as
seen
after
primary
two-dose
series,
did
correlate
perfectly
with
activity,
suggesting
simply
testing
measure
be
long-term
solution.
Therefore,
it
is
important
reassess
utility
testing,
current
strain-based
reliably
detect
reactive
antibodies
or
other
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(5), P. 471 - 471
Published: April 28, 2024
This
study
follows
99
subjects
vaccinated
with
Pfizer/BioNTech
COVID-19
vaccines
over
two
years,
particular
focus
on
the
last
year
of
observation
(between
days
360
and
720).
The
response
to
vaccination
was
assessed
Diasorin's
SARS-CoV-2
TrimericSpike
IgG.
Screening
for
infection
performed
Abbott's
Nucleocapsid
IgG
immunoassay.
Data
from
questionnaires
were
also
analyzed.
Two
years
after
first
vaccine
dose
administration,
100%
positive
anti-spike
median
antibody
level
still
high
(3600
BAU/mL),
dropping
insignificantly
year.
Simultaneously,
a
substantial
increase
in
seropositivity
anti-nucleocapsid
noted,
reaching
33%.
There
no
statistically
significant
agreement
between
anti-N
reported
COVID-19.
Higher
concentrations
lower
incidence
seen
older
vaccinees.
It
noted
that
only
boosted
720
showed
an
concentrations.
higher
(median
7440
BAU/mL)
day
participants
not
infected
following
Vaccination,
including
booster
administrations,
natural,
even
unrecognized,
contact
entwined
primary
vaccination,
leading
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Jan. 28, 2022
Recognizing
that
anti-SARS-CoV-2
antibody
levels
wane
over
time
following
the
2-dose
SARS-CoV-2
mRNA
series,
FDA
approved
a
booster
dose
for
people
greater
than
12
years
old.
Limited
data
exist
on
whether
of
vaccine
results
in
protection
primary
series.
We
examined
total
and
neutralizing
antibodies
to
spike
protein
SARS-CoV-2,
against
Washington-1
(WA-1)
variants
concern
(VOC)
including
Beta,
Delta
Omicron
longitudinal
cohort.
Healthcare
workers
(HWs)
were
included
analysis
if
serum
was
collected
1)
within
14-44
days
post-dose2
an
(Timepoint
1,
TP1),
or
2)
at
least
8
months
2,
TP2),
3)
3,
TP3).
HWs
with
prior
covid-positive
PCR
excluded.
found
there
is
little
no
capability
series
omicron
variant,
capacity
any
variant
strain
tested
has
been
lost
by
8-months
post
two-dose
vaccination
However,
eliminates
immune
escape
observed
Neutralizing
titers
significantly
higher
all
post-boost
compared
The
nature
our
cohort
facilitated
paired
samples
pre
boost,
showing
15-fold
increase
neutralization
these
samples.
An
provides
quantity
quality
regimen
critical
provide
variant.